These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 32657796)

  • 1. New targets and technologies for CAR-T cells.
    Freitag F; Maucher M; Riester Z; Hudecek M
    Curr Opin Oncol; 2020 Sep; 32(5):510-517. PubMed ID: 32657796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging CAR landscape for cancer immunotherapy.
    Lim FLWI; Ang SO
    Biochem Pharmacol; 2020 Aug; 178():114051. PubMed ID: 32446888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
    Salaroli A; Spilleboudt C; Bron D; Lewalle P
    Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
    Salmikangas P; Kinsella N; Chamberlain P
    Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CAR-T cells: Lymphocytes that express a chimeric antigen receptor].
    Chabannon C; Bouabdallah R; Fürst S; Granata A; Saillard C; Vey N; Mokart D; Fougereau E; Lemarie C; Mfarrej B; Blaise D; Calmels B
    Rev Med Interne; 2019 Aug; 40(8):545-552. PubMed ID: 30686549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures.
    Fu M; Tang L
    Recent Pat Anticancer Drug Discov; 2019; 14(1):60-69. PubMed ID: 30636615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials.
    Arabi F; Torabi-Rahvar M; Shariati A; Ahmadbeigi N; Naderi M
    Exp Cell Res; 2018 Aug; 369(1):1-10. PubMed ID: 29758187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.
    Alcantara M; Tesio M; June CH; Houot R
    Leukemia; 2018 Nov; 32(11):2307-2315. PubMed ID: 30315238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What CAR Will Win the CD19 Race?
    Quintás-Cardama A
    Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CAR T-cell therapy for T cell malignancies: challenges and recent advances].
    Tashiro H
    Rinsho Ketsueki; 2024; 65(7):644-651. PubMed ID: 39098015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies.
    Mochel JP; Ekker SC; Johannes CM; Jergens AE; Allenspach K; Bourgois-Mochel A; Knouse M; Benzekry S; Wierson W; LeBlanc AK; Kenderian SS
    AAPS J; 2019 Apr; 21(3):50. PubMed ID: 30963322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.
    Hughes-Parry HE; Cross RS; Jenkins MR
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.